Stifel analyst Thomas Stephan raised the firm’s price target on RxSight to $45 from $40 and keeps a Buy rating on the shares after the company announced “strong” preliminary Q4 results and gave “bullish” initial 2024 guidance. The results and guidance are “early validation of our view that RxSight is one of the better momentum stories in med-tech,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RXST:
- RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance
- RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
- RxSight price target raised by $7 at BTIG, here’s why
- RxSight price target raised to $43 from $36 at BTIG
- Microsoft initiated, Hertz downgraded: Wall Street’s top analyst calls
